Biomarker for ovarian and endometrial cancer: hepcidin
    1.
    发明申请
    Biomarker for ovarian and endometrial cancer: hepcidin 有权
    卵巢和子宫内膜癌的生物标记物:铁调素

    公开(公告)号:US20070054329A1

    公开(公告)日:2007-03-08

    申请号:US11373833

    申请日:2006-03-10

    IPC分类号: G01N33/574

    摘要: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.

    摘要翻译: 本发明提供了可用于鉴定卵巢癌状态以及患者中子宫内膜癌状态的基于蛋白质的生物标志物和生物标志物组合。 特别地,已经发现,铁调素是卵巢癌和子宫内膜癌的生物标志物,并且一组生物标志物,包括铁调素,转甲状腺素蛋白和任选的其他标记物可用于将受试者样品分类为卵巢癌或非卵巢癌。 生物标志物可以通过SELDI质谱检测。

    Biomaker for ovarian and endometrial cancer: hepcidin
    2.
    发明申请
    Biomaker for ovarian and endometrial cancer: hepcidin 审中-公开
    卵巢和子宫内膜癌的生物制剂:铁调素

    公开(公告)号:US20100068724A1

    公开(公告)日:2010-03-18

    申请号:US12381218

    申请日:2009-03-09

    IPC分类号: G01N33/53 G01N33/543

    摘要: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.

    摘要翻译: 本发明提供了可用于鉴定卵巢癌状态以及患者中子宫内膜癌状态的基于蛋白质的生物标志物和生物标志物组合。 特别地,已经发现,铁调素是卵巢癌和子宫内膜癌的生物标志物,并且一组生物标志物,包括铁调素,转甲状腺素蛋白和任选的其他标记物可用于将受试者样品分类为卵巢癌或非卵巢癌。 生物标志物可以通过SELDI质谱检测。

    Biomarker for ovarian and endometrial cancer: hepcidin
    3.
    发明授权
    Biomarker for ovarian and endometrial cancer: hepcidin 有权
    卵巢和子宫内膜癌的生物标记物:铁调素

    公开(公告)号:US07510842B2

    公开(公告)日:2009-03-31

    申请号:US11373833

    申请日:2006-03-10

    IPC分类号: G01N33/53

    摘要: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.

    摘要翻译: 本发明提供了可用于鉴定卵巢癌状态以及患者中子宫内膜癌状态的基于蛋白质的生物标志物和生物标志物组合。 特别地,已经发现,铁调素是卵巢癌和子宫内膜癌的生物标志物,并且一组生物标志物,包括铁调素,转甲状腺素蛋白和任选的其他标记物可用于将受试者样品分类为卵巢癌或非卵巢癌。 生物标志物可以通过SELDI质谱检测。